Patent · US Active

Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism

US9481709B2 · kind B2 · utility

0Cited by

16References

9Claims

0Family size

Assignee

OBE THERAPY BIOTECHNOLOGY · FR

Inventors

Itzik Harosh · Paris, FR
Sandrine Braud · Clermont-Ferrand, FR
Marco Ciufolini · Vancouver, CA

Key dates

Filing date	Dec 16, 2013
Grant date	Nov 1, 2016
Priority date	—
Expiry date	Dec 16, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel compounds, particularly derivatives of boroarginine, boroornithine and borolysine that selectively modulate, regulate, and/or inhibit enteropeptidase. Compositions, particularly pharmaceutical compositions, as well as methods to treat excess weight, obesity and diseases associated with an abnormal fat metabolism.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.